1. Alberts DS, Colvin OM, Conney AH, Ernster VL, Garber JE, Greenwald P, Gudas L, Hong KW, Kelloff GJ, Kramer RA, Lerman CE, Mangelsdorf DJ, Matter A, Minna JD, Nelson WG, Pezzuto JM, Prendergast F, Rusch VW, Sporn MB, Wattenberg LW, Weinstein IB: Prevention of cancer in the next millennium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res 59: 4743–4748, 1999
2. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK: Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Nat Cancer Inst 89: 199–211, 1997
3. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U: Effect of fenretinide on ovarian carcinoma occurrence. Gyn Oncol 86: 24–27, 2002
4. Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, Bacus J, Kagan V, Sexton KC, Grubbs CJ, Eltoum IE, Grizzle WE: The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol. Biomarkers Prev 12: 114–119, 2003
5. Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, Zou C, Hittelman WN, Lotan R, Hong WK: A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 7: 3356–3365, 2001